Skip to content
drillr.ai

STTK

Shattuck Labs, Inc.

NASDAQ · USHealthcareBiotechnology
$6.82-9.43%

Price as of Jul 20, 2026

STTK news

Shattuck Labs, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

    AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price pe

    Globe Newswire ·

  2. Shattuck Labs, Inc. Announces Proposed Public Offering

    AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so c

    Globe Newswire ·

  3. Shattuck Labs Announces Phase 1 Results for SL-325

    * Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies * Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higher * Well tolerated with a favorable safety profile consistent with the TL1A inhibitor class * No evidence of DR3 agonism * RECEPTIVE-CD1 Phase 2b clinical trial in patients with Crohn’s disease expected to initiate in the third quarter of 2026 * Lead bispecific product candidate,

    Globe Newswire ·

  4. Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

    * Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 – * Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the

    Globe Newswire ·

  5. Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

    * Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – * Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the trea

    Globe Newswire ·

  6. Shattuck Labs Announces Participation in Upcoming March Investor Conferences

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNX5Xn6D2&default-theme=true AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory a

    Globe Newswire ·